ESLA Key Statistics, Chart & Performance
The current stock price of ESLA is 1.81 USD. In the past month the price decreased by -20.61%. In the past year, price increased by 59.47%.
ESLA Latest News, Press Relases and Analysis
ESLA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.29 | 405.44B | ||
| AMGN | AMGEN INC | 15.29 | 179.97B | ||
| GILD | GILEAD SCIENCES INC | 15.3 | 155.44B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.42 | 108.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.92 | 80.71B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 851.43 | 56.92B | ||
| INSM | INSMED INC | N/A | 43.74B | ||
| NTRA | NATERA INC | N/A | 32.75B | ||
| BIIB | BIOGEN INC | 10.56 | 25.92B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.08 | 21.58B | ||
| INCY | INCYTE CORP | 16.55 | 20.75B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.12B |
Related stock screener links
About ESLA
Company Profile
Estrella Immunopharma, Inc. operates as a pre-clinical stage biopharmaceutical company, which engages in the development of T-cell therapies for patients with cancers and autoimmune diseases. The company is headquartered in Emeryville, California. The company went IPO on 2021-07-19. The firm is developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Its lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The firm is also developing EB104, which also utilizes Eureka's ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. The firm is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus (CF33-CD19t), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors. Its EB201 program, in preclinical development, is being explored as a potential therapeutic approach targeting Systemic Lupus Erythematosus (SLE).
Company Info
ESTRELLA IMMUNOPHARMA INC
5858 Horton St, Suite 370
Emeryville CALIFORNIA US
Employees: 0
Phone: 15103189098
ESTRELLA IMMUNOPHARMA INC / ESLA FAQ
What does ESTRELLA IMMUNOPHARMA INC do?
Estrella Immunopharma, Inc. operates as a pre-clinical stage biopharmaceutical company, which engages in the development of T-cell therapies for patients with cancers and autoimmune diseases. The company is headquartered in Emeryville, California. The company went IPO on 2021-07-19. The firm is developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Its lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The firm is also developing EB104, which also utilizes Eureka's ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. The firm is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus (CF33-CD19t), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors. Its EB201 program, in preclinical development, is being explored as a potential therapeutic approach targeting Systemic Lupus Erythematosus (SLE).
What is the stock price of ESTRELLA IMMUNOPHARMA INC today?
The current stock price of ESLA is 1.81 USD. The price increased by 19.08% in the last trading session.
Does ESTRELLA IMMUNOPHARMA INC pay dividends?
ESLA does not pay a dividend.
What is the ChartMill rating of ESTRELLA IMMUNOPHARMA INC stock?
ESLA has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is ESLA stock listed?
ESLA stock is listed on the Nasdaq exchange.
Can you provide the ownership details for ESLA stock?
You can find the ownership structure of ESTRELLA IMMUNOPHARMA INC (ESLA) on the Ownership tab.
ESLA Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to ESLA. When comparing the yearly performance of all stocks, ESLA is one of the better performing stocks in the market, outperforming 95.73% of all stocks.
ESLA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ESLA. ESLA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ESLA Financial Highlights
Over the last trailing twelve months ESLA reported a non-GAAP Earnings per Share(EPS) of -0.33. The EPS increased by 82.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -405.17% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ESLA Forecast & Estimates
7 analysts have analysed ESLA and the average price target is 16.32 USD. This implies a price increase of 801.66% is expected in the next year compared to the current price of 1.81.